This protease inhibitor shows two different activities, it inhibits both the capsaicin receptor TRPV1 and serine proteases. It partially (max 50%) and reversibly inhibits mammalian TRPV1, a non-selective cation channel expressed by sensory neurons of the pain pathway (Ref.2 (By similarity)). The second activity is a weak inhibition of trypsin and chymotrypsin activity (Ki=0.9 uM and Ki=4.5 uM, respectively) (PubMed:20208578). In vivo, shows analgesic effects on mammals (PubMed:20208578). Intravenous doses (up to 1 mg/kg) has no toxic effect and generated no behavioral disorders in mice. Belongs to the venom Kunitz-type family. Sea anemone type 2 potassium channel toxin subfamily.